Host factors influencing susceptibility to HIV infection and AIDS progression

Retrovirology

Volumn 4, Issue , 2007, Pages

  Lama, Juan ^a,b   Planelles, Vicente ^c  

^a LA JOLLA INSTITUTE FOR MOLECULAR MEDICINE   (United States)

^b RetroVirox   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; BETA CHEMOKINE; CD209 ANTIGEN; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR5 AGONIST; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CHEMOKINE RECEPTOR CXCR2; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR5; CYCLOPHILIN A; DEFENSIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; TOLL LIKE RECEPTOR; TRIPARTITE MOTIF PROTEIN 5; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CLINICAL TRIAL; DISEASE COURSE; DISEASE PREDISPOSITION; GENE FREQUENCY; GENE FUNCTION; GENE MUTATION; GENETIC CODE; GENETIC VARIABILITY; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOST SUSCEPTIBILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOMODULATION; INFECTION RISK; INNATE IMMUNITY; NONHUMAN; PATHOGENESIS; PHENOTYPE; PROTEIN DETERMINATION; PROTEIN FUNCTION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEROCONVERSION; SYMPTOM; VERTICAL TRANSMISSION; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS STRAIN; VIRUS TRANSMISSION; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION;

DISEASE PROGRESSION; DISEASE SUSCEPTIBILITY; HIV INFECTIONS; HUMANS; IMMUNITY, NATURAL; VARIATION (GENETICS);

EID: 34648840539     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-4-52     Document Type: Review

References (330)

1. Buchbinder SP Katz MH Hessol NA O'Malley PM Holmberg SD Long-term HIV-1 infection without immunologic progression. AIDS 1994, 8(8):1123-1128 10.1097/00002030-199408000-00014 7986410
2. Anastassopoulou CG Kostrikis LG The impact of human allelic variation on HIV-1 disease. Curr HIV Res 2003, 1(2)185-203 10.2174/1570162033485311 15043202
3. Telenti A Ioannidis JP Susceptibility to HIV infection - disentangling host genetics and host behavior. J Infect Dis 2006, 193(1):4-6 10.1086/ 498535 16323124
4. Cunningham AL Li S Juarez J Lynch G Alali M Naif H The level of HIV infection of macrophages is determined by interaction of viral and host cell genotypes. J Leukoc Biol 2000, 68(3):311-317 10985245
5. Blaak H Ran LJ Rientsma R Schuitemaker H Susceptibility of in vitro stimulated PBMC to infection with NSI HIV-1 is associated with levels of CCR5 expression and beta-chemokine production. Virology 2000, 267(2):237-246 10.1006/viro.1999.0111 10662619
6. Ciuffi A Bleiber G Munoz M Martinez R Loeuillet C Rehr M Fischer M Gunthard HF Oxenius A Meylan P Bonhoeffer S Trono D Telenti A Entry and transcription as key determinants of differences in CD4 T-cell permissiveness to human immunodeficiency virus type 1 infection. J Virol 2004, 78(19):10747-10754 10.1128/JVI.78.19.10747-10754.2004 15367641
7. Naif HM Li S Alali M Chang J Mayne C Sullivan J Cunningham AL Definition of the stage of host cell genetic restriction of replication of human immunodeficiency virus type 1 in monocytes and monocyte-derived macrophages by using twins. J Virol 1999, 73(6):4866-4881 10233948
8. Chang J Naif HM Li S Sullivan JS Randle CM Cunningham AL Twin studies demonstrate a host cell genetic effect on productive human immunodeficiency virus infection of human monocytes and macrophages in vitro. J Virol 1996, 70(11):7792-7803 8892900
9. Du Z Lang SM Sasseville VG Lackner AA Ilyinskii PO Daniel MD Jung JU Desrosiers RC Identification of a nef allele that causes lymphocyte activation and acute disease in macaque monkeys. Cell 1995, 82(4):665-674 10.1016/0092-8674(95)90038-1 7664345
10. Petrucci A Dorrucci M Alliegro MB Pezzotti P Rezza G Sinicco A Lazzarin A Angarano G How many HIV-infected individuals may be defined as long-term nonprogressors? A report from the Italian Seroconversion Study. Italian Seroconversion Study Group (ISS). J Acquir Immune Defic Syndr Hum Retrovirol 1997, 14(3):243-248 9117457
11. Shacklett BL Understanding the "lucky few": The conundrum of HIV-exposed, seronegative individuals. Curr HIV/AIDS Rep 2006, 3(1):26-31 10.1007/s11904-006-0005-2 16522256
12. Bleiber G May M Martinez R Meylan P Ott J Beckmann JS Telenti A Use of a combined ex vivo/in vivo population approach for screening of human genes involved in the human immunodeficiency virus type 1 life cycle for variants influencing disease progression. J Virol 2005, 79(20):12674-12680 10.1128/JVI.79.20.12674-12680.2005 16188970
13. Carrington M O'Brien SJ The influence of HLA genotype on AIDS Annu Rev Med 2003, 54:535-551 10.1146/annurev.med.54.101601.152346 12525683
14. Kaslow RA Dorak T Tang JJ Influence of host genetic variation on susceptibility to HIV type 1 infection J Infect Dis 2005, 191(Suppl 1):S68-77 10.1086/425269 15630678
15. O'Brien SJ Nelson GW Human genes that limit AIDS. Nat Genet 2004 36(6):565-574 10.1038/ng1369 15167933
16. Pierson TC Doms RW HIV-1 entry and its inhibition Curr Top Microbiol Immunol 2003 281:1-27 12932074
17. Arenzana-Seisdedos F Parmentier M Genetics of resistance to HIV infection: Role of co-receptors and co-receptor ligands. Semin Immunol 2006 18(6):387-403 10.1016/j.smim.2006.07.007 16978874
18. Feng Y Broder CC Kennedy PE Berger EA HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor [see comments] Science 1996 272:872-877 10.1126/science.272.5263.872 8629022
19. Alkhatib G Combadiere C Broder CC Feng Y Kennedy PE Murphy PM Berger EA CC CKR5: A rantes, MIP-1alpha, MIP-1beta receptor as fusion cofactor for macrophage tropic HIV-1 Science 1996, 272:5270-1955 1958 10.1126/ science.272.5270.1955 8658171
20. Choe H Farzan M sun Y Sullivan N Rollins B Ponath PD Wu L Mackay CR LaRosa G Newman W Gierard N Gerard C Sodroski J The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 1996 85(7):1135-1148 10.1016/S0092-8674(00)81313-6 8674119
21. Deng H Liu R Ellmeier W Choe S Unutmaz D Burkhart M Di Marzio P Marmon S Sutton R Hill CM Davis CB Peiper SC Schall TJ Littman DR Landau NR Identification of a major co-receptor for primary isolates of HIV-1 Nature 1996 381(6584):661-666 10.1038/381661a0 8649511
22. Doranz BJ Rucker J Yi Y Smyth RJ Samson M Peiper SC Parmentier M Collman RG Doms RW A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 1996 85(7):1149-1158 10.1016/S0092-8674(00)81314-8 8674120
23. Dragic T Litwin V Allaway GP Martin SR Huang Y Nagashima KA Cayanan C Maddon PJ Koup RA Moore JP Paxton WA HIV-1 entry into CD4-positive cells is mediated by the chemokine receptor CC-CKR-5 Nature 1996, 381(6584):667-673 10.1038/381667a0 8649512
24. Liu R Paxton WA Choe S Ceradini D Martin SR Horuk R MacDonald ME Stuhlmann H Koup RA Landau NR Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996, 86(3):367-377 10.1016/S0092-8674(00)80110-5 8756719
25. Dean M Carrington M Winkler C Huttley GA Smith MW Allikmets R Goedert JJ Buchbinder SP Vittinghoff E Gomperts E Donfield S Vlahov D Kaslow R Saah A Rinaldo C Detels R O'Brien SJ Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 1996, 273(5283):1856-1862 10.1126/ science.273.5283.1856 8791590
26. Samson M Libert F Doranz BJ Rucker J Liesnard C Farber CM Saragosti S Lapoumeroulie C Cognaux J Forceille C Muyldermans G Verhofstede C Burtonboy G Georges M Imai T Rana S Yi Y Smyth RJ Collman RG Doms RW Vassart G Parmentier M Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996, 382(6593):722-725 10.1038/382722a0 8751444
27. Benkirane M Jin DY Chun RF Koup RA Jeang KT Mechanism of transdominant inhibition of CCR5-mediated HIV-1 infection by ccr5delta32 J Biol Chem 1997, 272(49):30603-30606 10.1074/jbc.272.49.30603 9388191
28. Lederman MM Penn-Nicholson A Cho M Mosier D Biology of CCR5 and its role in HIV infection and treatment. Jama 2006, 296(7):815-826 10.1001/ jama.296.7.815 16905787
29. Stephens JC Reich DE Goldstein DB Shin HD Smith MW Carrington M Winkler C Huttley GA Allikmets R Schriml L Gerrard B Malasky M Ramos MD Morlot S Tzetis M Oddoux C di Giovine FS Nasioulas G Chandler D Aseev M Hanson M Kalaydjieva L Glavac D Gasparini P Kanavakis E Claustres M Kambouris M Ostrer H Duff G Baranov V Sibul H Metspalu A Goldman D Martin N Duffy D Schmidtke J Estivill X O'Brien SJ Dean M Dating the origin of the CCR5-Delta32 AIDS-resistance allele by the coalescence of haplotypes. Am J Hum Genet 1998, 62(6):1507-1515 10.1086/301867 9585595
30. Salkowitz JR Purvis SF Meyerson H Zimmerman P O'Brien TR Aledort L Eyster ME Hilgartner M Kessler C Konkle BA White GC II Goedert JJ Lederman MM Characterization of high-risk HIV-1 seronegative hemophiliacs. Clin Immunol 2001, 98(2):200-211 10.1006/clim.2000.4969 11161976
31. Naif HM Cunningham AL Alali M Li S Nasr N Buhler MM Schols D de Clercq E Stewart G A human immunodeficiency virus type 1 isolate from an infected person homozygous for CCR5Delta32 exhibits dual tropism by infecting macrophages and MT2 cells via CXCR4. J Virol 2002, 76(7):3114-3124 10.1128/JVI.76.7.3114-3124.2002 11884536
32. Gorry PR Zhang C Wu S Kunstman K Trachtenberg E Phair J Wolinsky S Gabuzda D Persistence of dual-tropic HIV-1 in an individual homozygous for the CCR5 Delta 32 allele. Lancet 2002, 359(9320)1832-1834 10.1016/ S0140-6736(02)08681-6 12044382
33. Michael NL Nelson JA KewalRamani VN Chang G O'Brien SJ Mascola JR Volsky B Louder M White GC II Littman DR Swanstrom R O'Brien TR Exclusive and persistent use of the entry coreceptor CXCR4 by human immunodeficiency virus type 1 from a subject homozygous for CCR5 delta32. J Virol 1998, 72(7):6040-6047 9621067
34. Balotta C Bagnarelli P Violin M Ridolfo AL Zhou D Berlusconi A Corvasce S Corbellino M Clementi M Clerici M Moroni M Galli M Homozygous delta 32 deletion of the CCR-5 chemokine receptor gene in an HIV-1-infected patient. AIDS 1997, 11(10):F67-71 10.1097/00002030-199710000-00001 9256936
35. Kuipers H Workman C Dyer W Geczy A Sullivan J Oelrichs R An HIV-1-infected individual homozygous for the CCR-5 delta32 allele and the SDF-1 3'A. allele AIDS 1999, 13(3):433-434 10.1097/ 00002030-199902250-00025 10199243
36. O'Brien TR Winkler C Dean M Nelson JA Carrington M Michael NL White GC II HIV-1 infection in a man homozygous for CCR5 delta 32. Lancet 1997, 349(9060):1219 10.1016/S0140-6736(97)24017-1 9130945
37. Theodorou I Meyer L Magierowska M Katlama C Rouzioux C HIV-1 infection in an individual homozygous for CCR5 delta 32. Seroco Study Group. Lancet 1997, 349(9060):1219-1220 10.1016/S0140-6736(05)62411-7 9130946
38. Cohen OJ Paolucci S Bende SM Daucher M Moriuchi H Moriuchi M Cicala C Davey RT Jr. Baird B Fauci AS CXCR4 and CCR5 genetic polymorphisms in long-term nonprogressive human immunodeficiency virus infection: Lack of association with mutations other than CCR5-Delta32. J Virol 1998, 72(7):6215-6217 9621092
39. Huang Y Paxton WA Wolinsky SM Neumann AU Zhang L He T Kang S Ceradini D Jin Z Yazdanbakhsh K Kunstman K Erickson D Dragon E Landau NR Phair J Ho DD Koup RA The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 1996 2(11):1240-1243 10.1038/nm1196-1240 8898752
40. Smith MW Dean M Carrington M Winkler C Huttley GA Lomb DA Goedert JJ O'Brien TR Jacobson LP Kaslow R Buchbinder S Vittinghoff E Vlahov D Hoots K Hilgartner MW O'Brien SJ Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study. Science 1997, 277(5328):959-965 10.1126/ science.277.5328.959 9252328
41. Stewart GJ Ashton LJ Biti RA Ffrench RA Bennetts BH Newcombe NR Benson EM Carr A Cooper DA Kaldor JM Increased frequency of CCR-5 delta 32 heterozygotes among long-term non-progressors with HIV-1 infection. The Australian Long-Term Non-Progressor Study Group. AIDS 1997, 11(15):1833-1838 10.1097/00002030-199715000-00007 9412701
42. Eskild A Jonassen TO Heger B Samuelsen SO Grinde B The estimated impact of the CCR-5 delta32 gene deletion on HIV disease progression varies with study design. Oslo HIV Cohort Study Group. AIDS 1998 12(17):2271-2274 10.1097/00002030-199817000-00007 9863868
43. Schinkel J Langendam MW Coutinho RA Krol A Brouwer M Schuitemaker H No evidence for an effect of the CCR5 delta32/+ and CCR2b 64I/+ mutations on human immunodeficiency virus (HIV)-1 disease progression among HIV-1-infected injecting drug users. J Infect Dis 1999, 179(4):825-831 10.1086/314658 10068577
44. Wilkinson DA Operskalski EA Busch MP Mosley JW Koup RA A 32-bp deletion within the CCR5 locus protects against transmission of parenterally acquired human immunodeficiency virus but does not affect progression to AIDS-defining illness. J Infect Dis 1998, 178(4):1163-1166 9806051
45. Morawetz RA Rizzardi GP Glauser D Rutschmann O Hirschel B Perrin L Opravil M Flepp M von Overbeck J Glauser MP Ghezzi S Vicenzi E Poli G Lazzarin A Pantaleo G Genetic polymorphism of CCR5 gene and HIV disease: the heterozygous (CCR5/delta ccr5) genotype is neither essential nor sufficient for protection against disease progression. Swiss HIV Cohort. Eur J Immunol 1997, 27(12):3223-3227 10.1002/eji.1830271220 9464809
46. Reynes J Portales P Segondy M Baillat V Andre P Avinens O Picot MC Clot J Eliaou JF Corbeau P CD4 T cell surface CCR5 density as a host factor in HIV-1 disease progression. AIDS 2001, 15(13):1627-1634 10.1097/ 00002030-200109070-00004 11546936
47. Reynes J Portales P Segondy M Baillat V Andre P Reant B Avinens O Couderc G Benkirane M Clot J Eliaou JF Corbeau P CD4 T cell surface CCR5 density as a determining factor of virus load in persons infected with human immunodeficiency virus type 1. J Inf Dis 2000, 181:927-932 10.1086/ 315315
48. Wu L Paxton WA Kassam N Ruffing N Rottman JB Sullivan N Choe H Sodroski J Newman W Koup RA Mackay CR CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro. J Exp Med 1997, 185(9):1681-1691 10.1084/jem.185.9.1681 9151905
49. Blanpain C Lee B Tackoen M Puffer B Boom A Libert F Sharron M Wittamer V Vassart G Doms RW Parmentier M Multiple nonfunctional alleles of CCR5 are frequent in various human populations. Blood 2000, 96(5):1638-1645 10961858
50. Capoulade-Metay C Trong LX Dudoit Y Versmisse P Nguyen NV Nguyen M Scott-Algara D Barre-Sinoussi F Debre P Bismuth G Pancino G Theodorou I New CCR5 variants associated with reduced HIV coreceptor function in southeast Asia AIDS 2004, 18(17):2243-2252 10.1097/ 00002030-200411190-00004 15577536
51. Carrington M Kissner T Gerrard B Ivanov S O'Brien SJ Dean M Novel alleles of the chemokine-receptor gene CCR5. Am J Hum Genet 1997, 61(6):1261-1267 10.1086/301645 9399903
52. Quillent C Oberlin E Braun J Rousset D Gonzalez-Canali G Metais P Montagnier L Virelizier JL Arenzana-Seisdedos F Beretta A HIV-1-resistance phenotype conferred by combination of two separate inherited mutations of CCR5 gene. Lancet 1998, 351(9095)14-18 10.1016/ S0140-6736(97)09185-X 9433423
53. Martin MP Dean M Smith MW Winkler C Gerrard B Michael NL Lee B Doms RW Margolick J Buchbinder S Goedert JJ O'Brien TR Hilgartner MW Vlahov D O'Brien SJ Carrington M Genetic acceleration of AIDS progression by a promoter variant of CCR5. Science 1998, 282(5395):1907-1911 10.1126/ science.282.5395.1907 9836644
54. Clegg AO Ashton LJ Biti RA Badhwar P Williamson P Kaldor JM Stewart GJ CCR5 promoter polymorphisms, CCR5 59029A and CCR5 59353C, are under represented in HIV-1-infected long-term non-progressors. The Australian Long-Term Non-Progressor Study Group. AIDS 2000, 14(2):103-108 10.1097/ 00002030-200001280-00004 10708279
55. Hladik F Liu H Speelmon E Livingston-Rosanoff D Wilson S Sakchalathorn P Hwangbo Y Greene B Zhu T McElrath MJ Combined effect of CCR5-Delta32 heterozygosity and the CCR5 promoter polymorphism -2459 A/G on CCR5 expression and resistance to human immunodeficiency virus type 1 transmission. J Virol 2005, 79(18):11677-11684 10.1128/ JVI.79.18.11677-11684.2005 16140745
56. Pastori C Weiser B Barassi C Uberti-Foppa C Ghezzi S Longhi R Calori G Burger H Kemal K Poli G Lazzarin A Lopalco L Long-lasting CCR5 internalization by antibodies in a subset of long-term nonprogressors: A possible protective effect against disease progression. Blood 2006, 107(12):4825-4233 10.1182/blood-2005-06-2463 16522810
57. Bouhlal H Latry V Requena M Aubry S Kaveri SV Kazatchkine MD Belec L Hocini H Natural antibodies to CCR5 from breast milk block infection of macrophages and dendritic cells with primary R5-tropic HIV-1. J Immunol 2005, 174(11):7202-7209 15905565
58. Barassi C Soprana E Pastori C Longhi R Buratti E Lillo F Marenzi C Lazzarin A Siccardi AG Lopalco L Induction of murine mucosal CCR5-reactive antibodies as an anti-human immunodeficiency virus strategy. J Virol 2005, 79(11):6848-6458 10.1128/ JVI.79.11.6848-6858.2005 15890924
59. Ray N Doms RW HIV-1 coreceptors and their inhibitors. Curr Top Microbiol Immunol 2006, 303:97-120 16570858
60. Kilby JM Eron JJ Novel therapies based on mechanisms of HIV-1 cell entry. N Engl J Med 2003, 348(22):2228-2238 10.1056/NEJMra022812 12773651
61. Fatkenheuer G Pozniak AL Johnson MA Plettenberg A Staszewski S Hoepelman AI Saag MS Goebel FD Rockstroh JK Dezube BJ Jenkins TM Medhurst C Sullivan JF Ridgway C Abel S James IT Youle M van der Ryst E Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med 2005, 11(11):1170-1172 10.1038/ nm1319 16205738
62. Smith MW Carrington M Winkler C Lomb D Dean M Huttley G O'Brien SJ CCR2 chemokine receptor and AIDS progression. Nat Med 1997, 3(10):1052-1053 10.1038/nm1097-1052c 9334699
63. Michael NL Louie LG Rohrbaugh AL Schultz KA Dayhoff DE Wang CE Sheppard HW The role of CCR5 and CCR2 polymorphisms in HIV-1 transmission and disease progression. Nat Med 1997, 3(10):1160-1162 10.1038/nm1097-1160 9334732
64. Lee B Doranz BJ Rana S Yi Y Mellado M Frade JM Martinez AC O'Brien SJ Dean M Collman RG Doms RW Influence of the CCR2-V64I polymorphism on human immunodeficiency virus type 1 coreceptor activity and on chemokine receptor function of CCR2b, CCR3, CCR5, and CXCR4. J Virol 1998, 72(9):7450-7458 9696841
65. Mariani R Wong S Mulder LC Wilkinson DA Reinhart AL LaRosa G Nibbs R O'Brien TR Michael NL Connor RI Macdonald M Busch M Koup RA Landau NR CCR2-64I polymorphism is not associated with altered CCR5 expression or coreceptor function. J Virol 1999, 73(3): 2450-2459 9971830
66. Nakayama EE Tanaka Y Nagai Y Iwamoto A Shioda T A CCR2-V64I polymorphism affects stability of CCR2A isoform. AIDS 2004, 18(5):729-738 10.1097/ 00002030-200403260-00003 15075507
67. Mellado M Rodriguez-Frade JM Vila-Coro AJ de Ana AM Martinez AC Chemokine control of HIV-1 infection. Nature 1999, 400(6746):723-724 10.1038/23382 10466720
68. Imai T Hieshima K Haskell C Baba M Nagira M Nishimura M Kakizaki M Takagi S Nomiyama H Schall TJ Yoshie O Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 1997, 91(4):521-530 10.1016/ S0092-8674(00)80438-9 9390561
69. Faure S Meyer L Costagliola D Vaneensberghe C Genin E Autran B Delfraissy JF McDermott DH Murphy PM Debre P Theodorou I Combadiere C Rapid progression to AIDS in HIV+ individuals with a structural variant of the chemokine receptor CX3CR1. Science 2000, 287(5461):2274 2277 10.1126/science.287.5461.2274 10731151
70. Singh KK Hughes MD Chen J Spector SA Genetic polymorphisms in CX3CR1 predict HIV-1 disease progression in children independently of CD4+ lymphocyte count and HIV-1 RNA load. J Infect Dis 2005, 191(11):1971-1980 10.1086/430091 15871132
71. Brumme ZL Dong WW Chan KJ Hogg RS Montaner JS O'Shaughnessy MV Harrigan PR Influence of polymorphisms within the CX3CR1 and MDR-1 genes on initial antiretroviral therapy response. AIDS 2003, 17(2):201-208 10.1097/00002030-200301240-00010 12545080
72. Vidal F Vilades C Domingo P Broch M Pedrol E Dalmau D Knobel H Peraire J Gutierrez C Sambeat MA Fontanet A Deig E Cairo M Montero M Richart C Mallal S Spanish HIV-1-infected long-term nonprogressors of more than 15 years have an increased frequency of the CX3CR1 249I variant allele. J Acquir Immune Defic Syndr 2005, 40(5):527-531 10.1097/ 01.qai.0000186362.50457.e0 16284527
73. Kwa D Boeser-Nunnink B Schuitemaker H Lack of evidence for an association between a polymorphism in CX3CR1 and the clinical course of HIV infection or virus phenotype evolution. AIDS 2003, 17(5):759-761 10.1097/00002030-200303280-00017 12646802
74. Puissant B Roubinet F Massip P Sandres-Saune K Apoil PA Abbal M Pasquier C Izopet J Blancher A Analysis of CCR5, CCR2, CX3CR1, and SDF1 polymorphisms in HIV-positive treated patients: Impact on response to HAART and on peripheral T lymphocyte counts. AIDS Res Hum Retroviruses 2006, 22(2):153-162 10.1089/aid.2006.22.153 16478397
75. McDermott DH Colla JS Kleeberger CA Plankey M Rosenberg PS Smith ED Zimmerman PA Combadiere C Leitman SF Kaslow RA Goedert JJ Berger EA O'Brien TR Murphy PM Genetic polymorphism in CX3CR1 and risk of HIV disease. Science 2000, 290(5499):2031 10.1126/science.290.5499.2031a 11187812
76. Faure S Meyer L Genin E Pellet P Debre P Theodorou I Combadiere C Deleterious genetic influence of CX3CR1 genotypes on HIV-1 disease progression. J Acquir Immune Defic Syndr 2003, 32(3):335-337 10.1097/ 00126334-200303010-00014 12626895
77. Koot M Keet IP Vos AH de Goede RE Roos MT Coutinho RA Miedema F Schellekens PT Tersmette M Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med 1993, 118(9):681-688 8096374
78. Cheng-Mayer C Seto D Tateno M Levy JA Biologic features of HIV-1 that correlate with virulence in the host. Science 1988, 240(4848):80-82 10.1126/science.2832945 2832945
79. Schuitemaker H Koot M Kootstra NA Dercksen MW de Goede RE van Steenwijk RP Lange JM Schattenkerk JK Miedema F Tersmette M Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: Progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population J Virol 1992, 66(3):1354-1360 1738194
80. Ho SH Shek L Gettie A Blanchard J Cheng-Mayer C V3 loop-determined coreceptor preference dictates the dynamics of CD4+-T-cell loss in simian-human immunodeficiency virus-infected macaques. J Virol 2005, 79(19):12296-12303 10.1128/JVI.79.19.12296-12303.2005 16160156
81. Karlsson I Antonsson L Shi Y Karlsson A Albert J Leitner T Olde B Owman C Fenyo EM HIV biological variability unveiled: Frequent isolations and chimeric receptors reveal unprecedented variation of coreceptor use. AIDS 2003, 17(18):2561-2569 10.1097/00002030-200312050-00003 14685050
82. Lusso P HIV and the chemokine system: 10 years later Embo J 2006, 25(3):447-456 10.1038/sj.emboj.7600947 16437164
83. Agace WW Amara A Roberts AI Pablos JL Thelen S Uguccioni M Li XY Marsal J Arenzana-Seisdedos F Delaunay T Ebert EC Moser B Parker CM Constitutive expression of stromal derived factor-1 by mucosal epithelia and its role in HIV transmission and propagation. Curr Biol 2000, 10(6):325-328 10.1016/S0960-9822(00)00380-8 10744978
84. Bunnik EM Quakkelaar ED van Nuenen AC Boeser-Nunnink B Schuitemaker H Increased neutralization sensitivity of recently emerged CXCR4-using human immunodeficiency virus type 1 strains compared to coexisting CCR5-using variants from the same patient. J Virol 2007, 81(2):525-531 10.1128/JVI.01983-06 17079299
85. Marodon G Warren D Filomio MC Posnett DN Productive infection of double-negative T cells with HIV in vivo Proc Natl Acad Sci USA 1999, 96(21):11958-11963 10.1073/pnas.96.21.11958 10518558
86. Menten P Wuyts A Van Damme J Macrophage inflammatory protein-1. Cytokine Growth Factor Rev 2002, 13(6):455-481 10.1016/S1359-6101(02)00045-X 12401480
87. Cocchi F DeVico AL Garzino-Demo A Arya SK Gallo RC Lusso P Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 1995, 270(5243):1811-1815 10.1126/science.270.5243.1811 8525373
88. Ullum H Cozzi Lepri A Victor J Aladdin H Phillips AN Gerstoft J Skinhoj P Pedersen BK Production of beta-chemokines in human immunodeficiency virus (HIV) infection: Evidence that high levels of macrophage inflammatory protein-1beta are associated with a decreased risk of HIV disease progression. J Infect Dis 1998, 177 (2):331-336 9466518
89. Saha K Bentsman G Chess L Volsky DJ Endogenous production of beta-chemokines by CD4+, but not CD8+, T-cell clones correlates with the clinical state of human immunodeficiency virus type 1 (HIV-1)-infected individuals and may be responsible for blocking infection with non-syncytium-inducing HIV-1 in vitro. J Virol 1998, 72(1):876-881 9420304
90. Koning FA Jansen CA Dekker J Kaslow RA Dukers N van Baarle D Prins M Schuitemaker H Correlates of resistance to HIV-1 infection in homosexual men with high-risk sexual behaviour AIDS 2004, 18(8):1117-1126 10.1097/ 00002030-200405210-00005 15166527
91. Saez-Cirion A Versmisse P Truong LX Chakrabarti LA Carpentier W Barre-Sinoussi F Scott-Algara D Pancino G Persistent resistance to HIV-1 infection in CD4 T cells from exposed uninfected Vietnamese individuals is mediated by entry and post-entry blocks. Retrovirology 2006, 3:81 10.1186/1742-4690-3-81 17092330
92. Amara A Gall SL Schwartz O Salamero J Montes M Loetscher P Baggiolini M Virelizier JL Arenzana-Seisdedos F HIV coreceptor downregulation as antiviral principle: SDF-1alpha-dependent internalization of the chemokine receptor CXCR4 contributes to inhibition of HIV replication. J Exp Med 1997, 186(1):139-146 10.1084/jem.186.1.139 9207008
93. Modi WS Lautenberger J An P Scott K Goedert JJ Kirk GD Buchbinder S Phair J Donfield S O'Brien SJ Winkler C Genetic variation in the CCL18-CCL3-CCL4 chemokine gene cluster influences HIV Type 1 transmission and AIDS disease progression. Am J Hum Genet 2006, 79(1):120-128 10.1086/505331 16773571
94. Vidal F Peraire J Domingo P Broch M Cairo M Pedrol E Montero M Vilades C Gutierrez C Sambeat MA Fontanet A Dalmau D Deig E Knobel H Sirvent JJ Richart C Veloso S Saumoy M Lopez-Dupla M Olona M Cadafalch J Fuster M Ochoa A Soler A Guelar A Gonzalez J Polymorphism of RANTES chemokine gene promoter is not associated with long-term nonprogressive HIV-1 infection of more than 16 years. J Acq ImM Def Syndr 2006, 41(1):17-22 10.1097/01.qai.0000188335.86466.ea
95. Irving SG Zipfel PF Balke J McBride OW Morton CC Burd PR Siebenlist U Kelly K Two inflammatory mediator cytokine genes are closely linked and variably amplified on chromosome 17q. Nucleic Acids Res 1990, 18(11):3261-3270 10.1093/nar/18.11.3261 1972563
96. Gonzalez E Kulkarni H Bolivar H Mangano A Sanchez R Catano G Nibbs RJ Freedman BI Quinones MP Bamshad MJ Murthy KK Rovin BH Bradley W Clark RA Anderson SA O'Connell R J Agan BK Ahuja SS Bologna R Sen L Dolan MJ Ahuja SK The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science 2005, 307(5714):1434-1440 10.1126/ science.1101160 15637236
97. Colobran R Adreani P Ashhab Y Llano A Este JA Dominguez O Pujol-Borrell R Juan M Multiple products derived from two CCL4 loci: High incidence of a new polymorphism in HIV+ patients. J Immunol 2005, 174(9):5655-5664 15843566
98. Gallo RC Garzino-Demo A DeVico AL HIV infection and pathogenesis: What about chemokines? J Clin Immunol 1999, 19(5):293-299 10.1023/ A:1020539524373 10535605
99. Zagury D Lachgar A Chams V Fall LS Bernard J Zagury JF Bizzini B Gringeri A Santagostino E Rappaport J Feldman M O'Brien SJ Burny A Gallo RC C-C chemokines, pivotal in protection against HIV type 1 infection. Proc Natl Acad Sci U S A 1998, 95(7):3857-3861 10.1073/pnas.95.7.3857 9520457
100. Liu H Chao D Nakayama EE Taguchi H Goto M Xin X Takamatsu JK Saito H Ishikawa Y Akaza T Juji T Takebe Y Ohishi T Fukutake K Maruyama Y Yashiki S Sonoda S Nakamura T Nagai Y Iwamoto A Shioda T Polymorphism in RANTES chemokine promoter affects HIV-1 disease progression Proc Natl Acad Sci U S A 1999, 96(8):4581-4585 10.1073/pnas.96.8.4581 10200305
101. Wichukchinda N Nakayama EE Rojanawiwat A Pathipvanich P Auwanit W Vongsheree S Ariyoshi K Sawanpanyalert P Shioda T Protective effects of IL4-589T and RANTES-28G on HIV-1 disease progression in infected Thai females. AIDS 2006, 20(2):189-196 10.1097/01.aids.0000199830.64735.6f 16511411
102. Zhao XY Lee SS Wong KH Chan KC Ma S Yam WC Yuen KY Ng MH Zheng BJ Effects of single nucleotide polymorphisms in the RANTES promoter region in healthy and HIV-infected indigenous Chinese. Eur J Immunogenet 2004, 31(4):179-183 10.1111/j.1365-2370.2004.00466.x 15265023
103. McDermott DH Beecroft MJ Kleeberger CA Al-Sharif FM Ollier WE Zimmerman PA Boatin BA Leitman SF Detels R Hajeer AH Murphy PM Chemokine RANTES promoter polymorphism affects risk of both HIV infection and disease progression in the Multicenter AIDS Cohort Study Aids 2000, 14(17):2671-2678 10.1097/00002030-200012010-00006 11125885
104. Fernandez RM Borrego S Marcos I Rubio A Lissen E Antinolo G Fluorescence resonance energy transfer analysis of the RANTES polymorphisms -403G → A and -28G→ C: Evaluation of both variants as susceptibility factors to HIV type 1 infection in the Spanish population. AIDS Res Hum Retroviruses 2003, 19(5):349-352 10.1089/088922203765551692 12803993
105. Winkler C An P O'Brien SJ Patterns of ethnic diversity among the genes that influence AIDS. Hum Mol Genet 2004, 13 Spec No 1 R9-19 10.1093/hmg/ ddh075 14764621
106. An P Nelson GW Donfield S Goederrt JJ Phair J Vlahov D Buchbinder S Farrar WL Modi W O'Brien S J Winkler CA Modulating influence on HIV/AIDS by interacting RANTES gene variants Proc Natl Acad Sci USA 2002, 99(15) 10002-10007 10.1073/pnas.142313799 12114533
107. Bleul CC Farzan M Choe H Parolin C Clark-Lewis I Sodroski J Springer TA The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature 1996, 382 (6594):829-833 10.1038/382829a0 8752280
108. Oberlin E Amara A Bachelerie F Bessia C Virelizier JL Arenzana-Seisdedos F Schwartz O Heard JM Clark-Lewis I Legler DF Loetscher M Baggiolini M Moser B The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature 1996, 382(6594):833-835 10.1038/382833a0 8752281
109. Signoret N Oldridge J Pelchen-Matthews A Klasse PJ Tran T Brass LF Rosenkilde MM Schwartz TW Holmes W Dallas W Luther MA Wells TN Hoxie JA Marsh M Phorbol esters and SDF-1 induce rapid endocytosis and down modulation of the chemokine receptor CXCR4. J Cell Biol 1997, 139(3):651-664 10.1083/jcb.139.3.651 9348282
110. Ma Q Jones D Borghesani PR Segal RA Nagasawa T Kishimoto T Bronson RT Springer TA Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice. Proc Natl Acad Sci USA 1998, 95(16):9448-9453 10.1073/pnas.95.16.9448 9689100
111. Nagasawa T Hirota S Tachibana K Takakura N Nishikawa S Kitamura Y Yoshida N Kikutani H Kishimoto T Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature 1996, 382(6592):635-638. 10.1038/382635a0 8757135
112. Arya SK Ginsberg CC Davis-Warren A D'Costa J In vitro phenotype of SDF1 gene mutant that delays the onset of human immunodeficiency virus disease in vivo J Hum Virol 1999. 2(3):133-138. 10413364
113. Winkler C Modi W Smith MW Nelson GW Wu X Carrington M Dean M Honjo T Tashiro K Yabe D Buchbinder S Vittinghoff E Goedert JJ O'Brien TR Jacobson LP Detels R Donfield S Willoughby A Gomperts E Vlahov D Phair J O'Brien SJ Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. ALIVE Study, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC) Science 1998, 279(5349):389-393. 10.1126/science.279.5349.389 9430590
114. Hendel H Henon N Lebuanec H Lachgar A Poncelet H Caillat-Zucman S Winkler CA Smith MW Kenefic L O'Brien S Lu W Andrieu JM Zagury D Schachter F Rappaport J Zagury JF Distinctive effects of CCR5, CCR2, and SDF1 genetic polymorphisms in AIDS progression. J Acquir Immune Defic Syndr Hum Retrovirol 1998, 19(4):381-386. 9833747
115. Ioannidis JP Rosenberg PS Goedert JJ Ashton LJ Benfield TL Buchbinder SP Coutinho RA Eugen-Olsen J Gallart T Katzenstein TL Kostrikis LG Kuipers H Louie LG Mallal SA Margolick JB Martinez OP Meyer L Michael NL
116. Magierowska M Lepage V Lien TX Lan NT Guillotel M Issafras H Reynes JM Fleury HJ Chi NH Follezou JY Debre P Theodorou I Barre-Sinoussi F Novel variant of the CCR5 gene in a Vietnamese population. Microbes Infect 1999, 1(2):123-124. 10.1016/S1286-4579(99)80002-1 10917742
117. Petersen DC Glashoff RH Shrestha S Bergeron J Laten A Gold B van Rensburg EJ Dean M Hayes VM Risk for HIV-1 infection associated with a common CXCL12 (SDF1) polymorphism and CXCR4 variation in an African population. J Acquir Immune Defic Syndr 2005, 40(5):521-526. 10.1097/ 01.qai.0000186360.42834.28 16284526
118. Modi WS Goedert JJ Strathdee S Buchbinder S Detels R Donfield S O'Brien SJ Winkler C MCP-1-MCP-3-Eotaxin gene cluster influences HIV-1 transmission. AIDS 2003, 17(16):2357-2365. 10.1097/ 00002030-200311070-00011 14571188
119. Ji X Gewurz H Spear GT Mannose binding lectin (MBL) and HIV. Mol Immunol 2005, 42(2):145-152. 10.1016/j.molimm.2004.06.015 15488604
120. Turville S Wilkinson J Cameron P Dable J Cunningham AL The role of dendritic cell C-type lectin receptors in HIV pathogenesis. J Leukoc Biol 2003, 74(5):710-718. 10.1189/jlb.0503208 12960229
121. Kwon DS Gregorio G Bitton N Hendrickson WA Littman DR DC-SIGN-mediated internalization of HIV is required for trans- enhancement of T cell infection. Immunity 2002, 16(1):135-144. 10.1016/S1074-7613(02)00259-5 11825572
122. Burleigh L Lozach PY Schiffer C Staropoli I Pezo V Porrot F Canque B Virelizier JL Arenzana-Seisdedos F Amara A Infection of dendritic cells (DCs), not DC-SIGN-mediated internalization of human immunodeficiency virus, is required for long-term transfer of virus to T cells. J Virol 2006, 80(6):2949-2957. 10.1128/JVI.80.6.2949-2957.2006 16501104
123. Martin MP Lederman MM Hutcheson HB Goedert JJ Nelson GW van Kooyk Y Detels R Buchbinder S Hoots K Vlahov D O'Brien SJ Carrington M Association of DC-SIGN promoter polymorphism with increased risk for parenteral, but not mucosal, acquisition of human immunodeficiency virus type 1 infection. J Virol 2004, 78(24):14053-14056. 10.1128/ JVI.78.24.14053-14056.2004 15564514
124. Gramberg T Zhu T Chaipan C Marzi A Liu H Wegele A Andrus T Hofmann H Pohlmann S Impact of polymorphisms in the DC-SIGNR neck domain on the interaction with pathogens. Virology 2006, 347(2):354-363. 10.1016/ j.virol.2005.11.033 16413044
125. Liu H Hwangbo Y Holte S Lee J Wang C Kaupp N Zhu H Celum C Corey L McElrath MJ Zhu T Analysis of genetic polymorphisms in CCR5, CCR2, stromal cell-derived factor-1, RANTES, and dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin in seronegative individuals repeatedly exposed to HIV-1. J Infect Dis 2004, 19096):1055-1058. 10.1086/423209 15319853
126. Santos PR Michel-Salzat A Butor C Chimpanzee DC-SIGN alleles predict the existence of A and B isoforms, but do not support a role for resistance to HIV infection. AIDS Res Hum Retroviruses 2005, 219(9):820-829. 10.1089/aid.2005.21.820 16218808
127. Fahrbach KM Barry SM Ayehunie S Lamore S Klausner M Hope TJ Activated CD34-Derived Langerhans Cells Mediate Transinfection with Human Immunodeficiency Virus. J Virol 2007, 81(13):6858-6868. 10.1128/ JVI.02472-06 17442711
128. de Witte L Nabatov A Pion M Fluitsma D de Jong MA de Gruijl T Piguet V van Kooyk Y Geijtenbeek TB Langerin is a natural barrier to HIV-1 transmission by Langerhans cells. Nat Med 2007, 13(3):367-371. 10.1038/ nm1541 17334373
129. Schwartz O Langerhans cells lap up HIV-1. Nat Med 2007, 139(3):245-246. 10.1038/nm0307-245 17342114
130. Verdijk P Dijkman R Plasmeijer EI Mulder AA Zoutman WH Mieke Mommaas A Tensen CP A lack of Birbeck granules in Langerhans cells is associated with a naturally occurring point mutation in the human Langerin gene J Invest Dermatol 2005, 124(4):714-717. 10.1111/j.0022-202X.2005.23645.x 15816828
131. Daher KA Selsted ME Lehrer RI Direct inactivation of viruses by human granulocyte defensins. J Virol 1986, 60(3):1068-1074. 3023659
132. Ganz T Selsted ME Szklarek D Harwig SS Daher K Bainton DF Lehrer RI Defensins. Natural peptide antibiotics of human neutrophils. J Clin Invest 1985, 76(4):1427-1435. 2997278
133. Cole AM Ganz T Human antimicrobial peptides: Analysis and application. Biotechniques 2000, 29(4):822 6, 828, 830-1. 11056814
134. Jenssen H Hamill P Hancock RE Peptide antimicrobial agents. Clin Microbiol Rev 2006, 19(3):491-511. 10.1128/CMR.00056-05 16847082
135. Klotman ME Chang TL Defensins in innate antiviral immunity. Nat Rev Immunol 2006, 6(6):447-456. 10.1038/nri1860 16724099
136. Nakashima H Yamamoto N Masuda M Fujii N Defensins inhibit HIV replication in vitro. AIDS 1993, 79(8):1129. 10.1097/ 00002030-199308000-00019 8397954
137. Tang YQ Yuan J Osapay G Osapay K Tran D Miller CJ Ouellette AJ Selsted ME A cyclic antimicrobial peptide produced in primate leukocytes by the ligation of two truncated alpha-defensins. Science 1999, 286(5439):498-502. 10.1126/science.286.5439.498 10521339
138. Cole AM Lehrer RI Minidefensins: Antimicrobial peptides with activity against HIV-1. Curr Pharm Des 2003, 9(18):1463-1473. 10.2174/ 1381612033454667 12769726
139. Cole AM Hong T Boo LM Nguyen T Zhao C Bristol G Zack JA Waring AJ Yang OO Lehrer RI Retrocyclin: A primate peptide that protects cells from infection by T- and M-tropic strains of HIV-1. Proc Natl Acad Sci USA 2002, 99(4):1813-1818. 10.1073/pnas.052706399 11854483
140. Gallo SA Wang W Rawat SS Jung G Waring AJ Cole AM Lu H Yan X Daly NL Craik DJ Jiang S Lehrer RI Blumenthal R Theta-defensins prevent HIV-1 Env-mediated fusion by binding gp41 and blocking 6-helix bundle formation. J Biol Chem 2006, 281(27):18787-18792. 10.1074/jbc.M602422200 16648135
141. Furci L Sironi F Tolazzi M Vassena L Lusso P Alpha-defensins block the early steps of HIV-1 infection: Interference with the binding of gp120 to CD4. Blood 2007, 109(7):2928-2935. 17132727
142. Chang TL Vargas J Jr. DelPortillo A Klotman ME Dual role of alpha-defensin-1 in anti-HIV-1 innate immunity. J Clin Invest 2005, 115(3):765-773. 10.1172/JCI200521948 15719067
143. Zhang L Yu W He T Yu J Caffrey RE Dalmasso EA Fu S Pham T Mei J Ho JJ Zhang W Lopez P Ho DD Contribution of Human alpha -Defensin 1, 2, and 3 to the Anti-HIV-1 Activity of CD8 Antiviral Factor. Science 2002, 298(5595):995-1000. 10.1126/science.1076185 12351674
144. Walker CM Moody DJ Stites DP Levy JA CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication. Science 1986, 234(4783):1563-1566. 10.1126/science.2431484 2431484
145. Levy JA The search for the CD8+ cell anti-HIV factor (CAF). Trends Immunol 2003, 24(12):628-632. 10.1016/j.it.2003.10.005 14644135
146. Mackewicz CE Yuan J Tran P Diaz L Mack E Selsted ME Levy JA alpha-Defensins can have anti-HIV activity but are not CD8 cell anti-HIV factors. AIDS 2003, 17(14):F23-32. 10.1097/00002030-200309260-00001 14502030
147. Schutte BC Mitros JP Bartlett JA Walters JD Jia HP Welsh MJ Casavant TL McCray PB Jr. Discovery of five conserved beta -defensin gene clusters using a computational search strategy. Proc Natl Acad Sci USA 2002, 99(4):2129-2133. 10.1073/pnas.042692699 11854508
148. Weinberg A Quinones-Mateu ME Lederman MM Role of human beta-defensins in HIV infection. Adv Dent Res 2006, 19(1):42-48. 16672548
149. Sun L Finnegan CM Kish-Catalone T Blumenthal R Garzino-Demo P La Terra Maggiore GM Berrone S Kleinman C Wu Z Abdelwahab S Lu W Garzino-Demo A Human beta-defensins suppress human immunodeficiency virus infection: potential role in mucosal protection. J Virol 2005, 79(22):14318-14329. 10.1128/JVI.79.22.14318-14329.2005 16254366
150. Feng Z Dubyak GR Lederman MM Weinberg A Cutting edge: Human beta defensin 3 - a novel antagonist of the HIV-1 coreceptor CXCR4. J Immunol 2006, 177(2):782-786. 16818731
151. Quinones-Mateu ME Lederman MM Feng Z Chakraborty B Weber J Rangel HR Marotta ML Mirza M Jiang B Kiser P Medvik K Sieg SF Weinberg A Human epithelial beta-defensins 2 and 3 inhibit HIV-1 replication. AIDS 2003, 17(16):F39-48. 10.1097/00002030-200311070-00001 14571200
152. Sun L Demasi L Lafferty M Goicochea M Lu W Garzino-Demo A CCR6 mediates the intracellular HIV inhibitory activity of human beta-defensin 2. Retrovirology 2006, 3 Suppl 1:S77. 10.1186/1742-4690-3-S1-S77
153. Armogida SA Yannaras NM Melton AL Srivastava MD Identification and quantification of innate immune system mediators in human breast milk. Allergy Asthma Proc 2004, 25(5):297-304. 15603202
154. Jia HP Starner T Ackermann M Kirby P Tack BF McCray PB Jr. Abundant human beta-defensin-1 expression in milk and mammary gland epithelium. J Pediatr 2001, 138(1):109-112. 10.1067/mpd.2001.109375 11148522
155. Kuhn L Trabattoni D Kankasa C Semrau K Kasonde P Lissoni F Sinkala M Ghosh M Vwalika C Aldrovandi GM Thea DM Clerici M Alpha-defensins in the prevention of HIV transmission among breastfed infants. J Acquir Immune Defic Syndr 2005, 39(2):138-142. 15905728
156. Braida L Boniotto M Pontillo A Tovo PA Amoroso A Crovella S A single-nucleotide polymorphism in the human beta-defensin 1 gene is associated with HIV-1 infection in Italian children. AIDS 2004, 18(11):1598-1600. 10.1097/01.aids.0000131363.82951.fb 15238780
157. Segat L Milanese M Boniotto M Crovella S Bernardon M Costantini M Alberico S DEFB-1 genetic polymorphism screening in HIV-1 positive pregnant women and their children. J Matern Fetal Neonatal Med 2006, 19(1):13-16. 10.1080/14767050500381123 16572527
158. Milanese M Segat L Pontillo A Arraes LC de Lima Filho JL Crovella S DEFB1 gene polymorphisms and increased risk of HIV-1 infection in Brazilian children. AIDS 2006, 209(12):1673-1675. 10.1097/ 01.aids.0000238417.05819.40 16868452
159. Trabattoni D Caputo SL Maffeis G Vichi F Biasin M Pierotti P Fasano F Saresella M Franchini M Ferrante P Mazzotta F Clerici M Human alpha defensin in HIV-exposed but uninfected individuals. J Acquir Immune Defic Syndr 2004, 35(5):455-463. 10.1097/00126334-200404150-00003 15021310
160. Aldred PM Hollox EJ Armour JA Copy number polymorphism and expression level variation of the human alpha-defensin genes DEFA1 and DEFA3. Hum Mol Genet 2005, 14(14):2045-2052. 10.1093/hmg/ddi209 15944200
161. Hollox EJ Armour JA Barber JC Extensive normal copy number variation of a beta-defensin antimicrobial-gene cluster. Am J Hum Genet 2003, 739(3):591-600. 10.1086/378157 12916016
162. Mars WM Patmasiriwat P Maity T Huff V Weil MM Saunders GF Inheritance of unequal numbers of the genes encoding the human neutrophil defensins HP-1 and HP-3. J Biol Chem 1995, 270(51):30371-30376. 10.1074/ jbc.270.51.30371 8530462
163. Handschumacher RE Harding MW Rice J Drugge RJ Speicher DW Cyclophilin: A specific cytosolic binding protein for cyclosporin A. Science 1984, 226(4674):544-547. 10.1126/science.6238408 6238408
164. Sandstrom EG Kaplan JC Antiviral therapy in AIDS. Clinical pharmacological properties and therapeutic experience to date. Drugs 1987, 34(3):372-390. 2824170
165. Klatzmann D Laporte JP Achour A Brisson E Gruest J Montagnier L Gluckman JC Functional inhibition by cyclosporin A of the lymphocyte receptor for the AIDS virus (HIV) C R Acad Sci III 1986, 303(9):343-348. 3096516
166. Luban J Bossolt KL Franke EK Kalpana GV Goff SP Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B. Cell 1993, 73(6):1067-1078. 10.1016/0092-8674(93)90637-6 8513493
167. Franke EK Yuan HE Luban J Specific incorporation of cyclophilin A into HIV-1 virions. Nature 1994, 372(6504):359-362. 10.1038/372359a0 7969494
168. Ott DE Coren LV Johnson DG Sowder RC 2nd Arthur LO Henderson LE Analysis and localization of cyclophilin A found in the virions of human immunodeficiency virus type 1 MN strain. AIDS Res Hum Retroviruses 1995, 11(9):1003-1006. 8554896
169. Thali M Bukovsky A Kondo E Rosenwirth B Walsh CT Sodroski J Gottlinger HG Functional association of cyclophilin A with HIV-1 virions. Nature 1994, 372(6504):363-365. 10.1038/372363a0 7969495
170. Besnier C Takeuchi Y Towers G Restriction of lentivirus in monkeys Proc Natl Acad Sci USA 2002, 99(18):11920-11925. 10.1073/pnas.172384599 12154231
171. Cowan S Hatziioannou T Cunningham T Muesing MA Gottlinger HG Bieniasz PD Cellular inhibitors with Fv1-like activity restrict human and simian immunodeficiency virus tropism. Proc Natl Acad Sci USA 2002, 99(18):11914-11919. 10.1073/pnas.162299499 12154227
172. Munk C Brandt SM Lucero G Landau NR A dominant block to HIV-1 replication at reverse transcription in simian cells. Proc Natl Acad Sci USA 2002, 99(21):13843-13848. 10.1073/pnas.212400099 12368468
173. Hatziioannou T Perez-Caballero D Cowan S Bieniasz PD Cyclophilin interactions with incoming human immunodeficiency virus type 1 capsids with opposing effects on infectivity in human cells. J Virol 2005, 79(1):176-183. 10.1128/JVI.79.1.176-183.2005 15596813
174. Sokolskaja E Sayah DM Luban J Target cell cyclophilin A modulates human immunodeficiency virus type 1 infectivity. J Virol 2004, 78(23):12800-12808. 10.1128/JVI.78.23.12800-12808.2004 15542632
175. Luban J Cyclophilin A, TRIM5, and Resistance to HIV-1 Infection. J Virol 2006, 81(3):1054-1061. 10.1128/JVI.01519-06 16956947
176. Fischer G Tradler T Zarnt T The mode of action of peptidyl prolyl cis/ trans isomerases in vivo: Binding vs. catalysis. FEBS Lett 1998, 426(1):17-20. 10.1016/S0014-5793(98)00242-7 9598969
177. Coaker G Falick A Staskawicz B Activation of a phytopathogenic bacterial effector protein by a eukaryotic cyclophilin. Science 2005, 308(5721):548-550. 10.1126/science.1108633 15746386
178. Stremlau M Owens CM Perron MJ Kiessling M Autissier P Sodroski J The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 2004, 427(6977):848-853. 10.1038/nature02343 14985764
179. Keckesova Z Ylinen LM Towers GJ Cyclophilin A renders human immunodeficiency virus type 1 sensitive to Old World monkey but not human TRIM5 alpha antiviral activity. J Virol 2006, 80(10);4683-4690. 10.1128/JVI.80.10.4683-4690.2006 16641261
180. Sokolskaja E Berthoux L Luban J Cyclophilin A and TRIM5alpha independently regulate human immunodeficiency virus type 1 infectivity in human cells. J Virol 2006, 80(6):2855-2862. 10.1128/ JVI.80.6.2855-2862.2006 16501094
181. Stremlau M Song B Javanbakht H Perron M Sodroski J Cyclophilin A: An auxiliary but not necessary cofactor for TRIM5alpha restriction of HIV-1. Virology 2006, 351(1):112-120. 16643975
182. Speelmon EC Livingston-Rosanoff D Li SS Vu Q Bui J Geraghty DE Zhao LP McElrath MJ Genetic association of the antiviral restriction factor TRIM5alpha with human immunodeficiency virus type 1 infection. J Virol 2006, 80(5):2463-2471. 10.1128/JVI.80.5.2463-2471.2006 16474153
183. Javanbakht H An P Gold B Petersen DC O'Huigin C Nelson GW O'Brien SJ Kirk GD Detels R Buchbinder S Donfield S Shulenin S Song B Perron MJ Stremlau M Sodroski J Dean M Winkler C Effects of human TRIM5alpha polymorphisms on antiretroviral function and susceptibility to human immunodeficiency virus infection. Virology 2006, 354(1):15-27. 10.1016/ j.virol.2006.06.031 16887163
184. Goldschmidt V Bleiber G May M Martinez R Ortiz M Telenti A Role of common human TRIM5alpha variants in HIV-1 disease progression. Retrovirology 2006, 3:54. 10.1186/1742-4690-3-54 16925802
185. Harris RS Bishop KN Sheehy AM Craig HM Petersen-Mahrt SK Watt IN Neuberger MS Malim MH DNA deamination mediates innate immunity to retroviral infection. Cell 2003, 113(6):803-809. 10.1016/ S0092-8674(03)00423-9 12809610
186. Mangeat B Turelli P Caron G Friedli M Perrin L Trono D Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 2003, 424(6944):99-103. 10.1038/ nature01709 12808466
187. Zhang H Yang B Pomerantz RJ Zhang C Arunachalam SC Gao L The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 2003, 424(6944);94-98. 10.1038/nature01707 12808465
188. Lecossier D Bouchonnet F Clavel F Hance AJ Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science 2003, 300(5622):1112. 10.1126/ science.1083338 12750511
189. Mariani R Chen D Schrofelbauer B Navarro F Konig R Bollman B Munk C Nymark-McMahon H Landau NR Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 2003, 114(1):21-31. 10.1016/ S0092-8674(03)00515-4 12859895
190. Yu Q Konig R Pillai S Chiles K Kearney M Palmer S Richman D Coffin JM Landau NR Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat Struct Mol Biol 2004, 11(5):435-442. 10.1038/nsmb758 15098018
191. Turelli P Mangeat B Jost S Vianin S Trono D Inhibition of hepatitis B virus replication by APOBEC3G. Science 2004, 303(5665):1829. 10.1126/ science.1092066 15031497
192. Newman EN Holmes RK Craig HM Klein KC Lingappa JR Malim MH Sheehy AM Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity Curr Biol 2005, 15(2):166-170. 10.1016/ j.cub.2004.12.068 15668174
193. Chiu YL Witkowska HE Hall SC Santiago M Soros VB Esnault C Heidmann T Greene WC High-molecular-mass APOBEC3G complexes restrict Alu retrotransposition Proc Natl Acad Sci USA 2006, 103(42):15588-15593. 10.1073/pnas.0604524103 17030807
194. Schumacher AJ Nissley DV Harris RS APOBEC3G hypermutates genomic DNA and inhibits Ty1 retrotransposition in yeast Proc Natl Acad Sci USA 2005, 102(28):9854-9859. 10.1073/pnas.0501694102 16000409
195. Esnault C Heidmann O Delebecque F Dewannieux M Ribet D Hance AJ Heidmann T Schwartz O APOBEC3G cytidine deaminase inhibits retrotransposition of endogenous retroviruses. Nature 2005, 433(7024):430-433. 10.1038/ nature03238 15674295
196. Gu Y Kodama H Watanabe S Kikuchi N Ishitsuka I Ozawa H Fujisawa C Shiga K The first reported case of Menkes disease caused by an Alu insertion mutation. Brain Dev 2007, 29(2):105-108. 10.1016/j.braindev.2006.05.012 17178205
197. Deininger PL Batzer MA Alu repeats and human disease Mol Genet Metab 1999, 67(3):183-193. 10.1006/mgme.1999.2864 10381326
198. Apoil PA Kuhlein E Robert A Rubie H Blancher A HIGM syndrome caused by insertion of an AluYb8 element in exon 1 of the CD40LG gene. Immunogenetics 2007, 59(1):17-23. 10.1007/s00251-006-0175-5 17146684
199. Marin M Rose KM Kozak SL Kabat D HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation Nat Med 2003, 9(11):1398-1403. 10.1038/nm946 14528301
200. Yu X Yu Y Liu B Luo K Kong W Mao P Yu XF Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 2003, 302(5647):1056-1060. 10.1126/science.1089591 14564014
201. Mehle A Strack B Ancuta P Zhang C McPike M Gabuzda D Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway. J Biol Chem 2004, 2799):7792-7798. 10.1074/jbc.M313093200 14672928
202. Mehle A Goncalves J Santa-Marta M McPike M Gabuzda D Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation. Genes Dev 2004, 18(23):2861-2866. 10.1101/ gad.1249904 15574592
203. Hassaine G Agostini I Candotti D Bessou G Caballero M Agut H Autran B Barthalay Y Vigne R Characterization of human immunodeficiency virus type 1 vif gene in long-term asymptomatic individuals. Virology 2000, 276(1):169-180. 10.1006/viro.2000.0543 11022005
204. Alexander L Aquino-DeJesus M Chan M Andiman WA Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by two-amino-acid insertion in HIV-1 vif from nonprogressing mother and child. J Virol 2002, 76(20):10533-10539. 10.1128/JVI.76.20.10533-10539.2002 12239333
205. Farrow MA Somasundaran M Zhang C Gabuzda D Sullivan JL Greenough TC Nuclear localization of HIV type 1 Vif isolated from a long-term asymptomatic individual and potential role in virus attenuation. AIDS Res Hum Retroviruses 2005, 21(6):565-574. 10.1089/aid.2005.21.565 15989462
206. An P Bleiber G Duggal P Nelson G May M Mangeat B Alobwede I Trono D Vlahov D Donfield S Goedert JJ Phair J Buchbinder S O'Brien SJ Telenti A Winkler CA APOBEC3G genetic variants and their influence on the progression to AIDS. J Virol 2004, 78(20):11070-11076. 10.1128/ JVI.78.20.11070-11076.2004 15452227
207. Do H Vasilescu A Diop G Hirtzig T Heath SC Coulonges C Rappaport J Therwath A Lathrop M Matsuda F Zagury JF Exhaustive genotyping of the CEM15 (APOBEC3G) gene and absence of association with AIDS progression in a French cohort. J Infect Dis 2005, 191(2):159-163. 10.1086/426826 15609224
208. Valcke HS Bernard NF Bruneau J Alary M Tsoukas CM Roger M APOBEC3G genetic variants and their association with risk of HIV infection in highly exposed Caucasians. AIDS 2006, 20(15):1984-1986. 10.1097/ 01.aids.0000247124.35129.e1 16988524
209. Jin X Brooks A Chen H Bennett R Reichman R Smith H APOBEC3G/CEM15 (hA3G) mRNA levels associate inversely with human immunodeficiency virus viremia. J Virol 2005, 79(17):11513-11516. 10.1128/ JVI.79.17.11513-11516.2005 16103203
210. An P Duggal P Wang LH O'Brien SJ Donfield S Goedert JJ Phair J Buchbinder S Kirk GD Winkler CA Polymorphisms of CUL5 are associated with CD4+ T cell loss in HIV-1 infected individuals. PLoS Genet 2007, 3(1);e19. 10.1371/journal.pgen.0030019 17257057
211. Varthakavi V Smith RM Bour SP Strebel K Spearman P Viral protein U counteracts a human host cell restriction that inhibits HIV-1 particle production. Proc Natl Acad Sci USA 2003, 100(25):15154-15159. 10.1073/ pnas.2433165100 14657387
212. Neil SJ Eastman SW Jouvenet N Bieniasz PD HIV-1 Vpu promotes release and prevents endocytosis of nascent retrovirus particles from the plasma membrane. PLoS Pathog 2006, 2(5):e39. 10.1371/journal.ppat.0020039 16699598
213. Hsu K Seharaseyon J Dong P Bour S Marban E Mutual functional destruction of HIV-1 Vpu and host TASK-1 channel. Mol Cell 2004, 14(2):259-267. 10.1016/S1097-2765(04)00183-2 15099524
214. Strebel K HIV-1 Vpu: Putting a channel to the TASK. Mol Cell 2004, 14(2);150-152. 10.1016/S1097-2765(04)00205-9 15099514
215. Akari H Bour S Kao S Adachi A Strebel K The Human Immunodeficiency Virus Type 1 Accessory Protein Vpu Induces Apoptosis by Suppressing the Nuclear Factor kappaB-dependent Expression of Antiapoptotic Factors J Exp Med 2001, 194(9):1299-1312. 10.1084/jem.194.9.1299 11696595
216. Margottin F Bour SP Durand H Selig L Benichou S Richard V Thomas D Strebel K Benarous R A novel human WD protein, h-beta TrCp, that interacts with HIV-1 Vpu connects CD4 to ER degradation pathway through an F-box motif. Mol Cell 1998, 4:565-574. 10.1016/S1097-2765(00)80056-8
217. Garrus JE von Schwedler UK Pornillos OW Morham SG Zavitz KH Wang HE Wettstein DA Stray KM Cote M Rich RL Myszka DG Sundquist WI Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding. Cell 2001, 107(1):55-65. 10.1016/S0092-8674(01)00506-2 11595185
218. VerPlank L Bouamr F LaGrassa TJ Agresta B Kikonyogo A Leis J Carter CA Tsg101, a homologue of ubiquitin-conjugating (E2) enzymes, binds the L domain in HIV type 1 Pr55(Gag). Proc Natl Acad Sci USA 2001, 98(14):7724-7729. 10.1073/pnas.131059198 11427703
219. Martin-Serrano J Zang T Bieniasz PD HIV-1 and Ebola virus encode small peptide motifs that recruit Tsg101 to sites of particle assembly to facilitate egress. Nat Med 2001, 7(12):1313-1319. 10.1038/nm1201-1313 11726971
220. Welsch S Keppler OT Habermann A Allespach I Krijnse-Locker J Krausslich HG HIV-1 buds predominantly at the plasma membrane of primary human macrophages. PLoS Pathog 2007, 3(3):e36 10.1371/journal.ppat.0030036 17381240
221. Jouvenet N Neil SJ Bess C Johnson MC Virgen CA Simon SM Bieniasz PD Plasma membrane is the site of productive HIV-1 particle assembly. PLoS Biol 2006, 4(12):e435. 10.1371/journal.pbio.0040435 17147474
222. Deneka M Pelchen-Matthews A Byland R Ruiz-Mateos E Marsh M In macrophages, HIV-1 assembles into an intracellular plasma membrane domain containing the tetraspanins CD81, CD9, and CD53. J Cell Biol 2007, 177(2):329-341. 10.1083/jcb.200609050 17438075
223. Morita E Sundquist WI Retrovirus budding Annu Rev Cell Dev Biol 2004 20 395 425 10.1146/annurev.cellbio.20.010403.102350 15473846
224. von Schwedler UK Stuchell M Muller B Ward DM Chung HY Morita E Wang HE Davis T He GP Cimbora DM Scott A Krausslich HG Kaplan J Morham SG Sundquist WI The protein network of HIV budding. Cell 2003, 114(6):701-713. 10.1016/S0092-8674(03)00714-1 14505570
225. Amit I Yakir L Katz M Zwang Y Marmor MD Citri A Shtiegman K Alroy I Tuvia S Reiss Y Roubini E Cohen M Wides R Bacharach E Schubert U Yarden Y Tal, a Tsg101-specific E3 ubiquitin ligase, regulates receptor endocytosis and retrovirus budding. Genes Dev 2004, 18(14):1737-1752. 10.1101/gad.294904 15256501
226. Eastman SW Martin-Serrano J Chung W Zang T Bieniasz PD Identification of human VPS37C, a component of endosomal sorting complex required for transport-I important for viral budding. J Biol Chem 2005, 280(1):628-636. 10.1074/jbc.M413556200 15509564
227. Strack B Calistri A Craig S Popova E Gottlinger HG AIP1/ALIX is a binding partner for HIV-1 p6 and EIAV p9 functioning in virus budding. Cell 2003, 114(6):689-699. 10.1016/S0092-8674(03)00653-6 14505569
228. Stuchell MD Garrus JE Muller B Stray KM Ghaffarian S McKinnon R Krausslich HG Morham SG Sundquist WI The human endosomal sorting complex required for transport (ESCRT-I) and its role in HIV-1 budding. J Biol Chem 2004, 279(34):36059-360571. 10.1074/jbc.M405226200 15218037
229. Bashirova AA Bleiber G Qi Y Hutcheson H Yamashita T Johnson RC Cheng J Alter G Goedert JJ Buchbinder S Hoots K Vlahov D May M Maldarelli F Jacobson L O'Brien S J Telenti A Carrington M Consistent effects of TSG101 genetic variability on multiple outcomes of exposure to human immunodeficiency virus type 1. J Virol 2006, 80(14):6757-6763. 10.1128/ JVI.00094-06 16809281
230. Smith MS Thresher RJ Pagano JS Inhibition of human immunodeficiency virus type 1 morphogenesis in T cells by alpha interferon. Antimicrob Agents Chemother 1991, 35(1):62-67. 1707604
231. Yasuda Y Miyake S Kato S Kita M Kishida T Kimura T Ikuta K Interferon-alpha treatment leads to accumulation of virus particles on the surface of cells persistently infected with the human immunodeficiency virus type 1 J Acquir Immune Defic Syndr 1990, 3(11):1046-1051. 2213506
232. Okumura A Lu G Pitha-Rowe I Pitha PM Innate antiviral response targets HIV-1 release by the induction of ubiquitin-like protein ISG15 Proc Natl Acad Sci USA 2006, 103(5):1440-1445. 10.1073/pnas.0510518103 16434471
233. Dooher JE Schneider BL Reed JC Lingappa JR Host ABCE1 is at Plasma Membrane HIV Assembly Sites and Its Dissociation from Gag is Linked to Subsequent Events of Virus Production. Traffic 2007, 8(3):195-211. 10.1111/j.1600-0854.2006.00524.x 17233757
234. Lingappa JR Dooher JE Newman MA Kiser PK Klein KC Basic residues in the nucleocapsid domain of Gag are required for interaction of HIV-1 gag with ABCE1 (HP68), a cellular protein important for HIV-1 capsid assembly. J Biol Chem 2006, 281(7):3773-3784. 10.1074/jbc.M507255200 16275648
235. Zimmerman C Klein KC Kiser PK Singh AR Firestein BL Riba SC Lingappa JR Identification of a host protein essential for assembly of immature HIV- 1 capsids. Nature 2002, 415(6867):88-92. 10.1038/415088a 11780123
236. Dong X Li H Derdowski A Ding L Burnett A Chen X Peters TR Dermody TS Woodruff E Wang JJ Spearman P AP-3 directs the intracellular trafficking of HIV-1 Gag and plays a key role in particle assembly. Cell 2005, 120(5):663-674. 10.1016/j.cell.2004.12.023 15766529
237. Huizing M Gahl WA Disorders of vesicles of lysosomal lineage: The Hermansky-Pudlak syndromes. Curr Mol Med 2002, 2(5):451-467. 10.2174/ 1566524023362357 12125811
238. Hammarstedt M Garoff H Passive and active inclusion of host proteins in human immunodeficiency virus type 1 gag particles during budding at the plasma membrane. J Virol 2004, 78(11):5686-5697. 10.1128/ JVI.78.11.5686-5697.2004 15140966
239. Tremblay MJ Fortin JF Cantin R The acquisition of host-encoded proteins by nascent HIV-1. Immunol Today 1998, 19(8):346-351. 10.1016/ S0167-5699(98)01286-9 9709501
240. Fortin JF Cantin R Lamontagne G Tremblay M Host-derived ICAM-1 glycoproteins incorporated on human immunodeficiency virus type 1 are biologically active and enhance viral infectivity J Virol 1997, 71(5):3588-3596. 9094631
241. Bounou S Leclerc JE Tremblay MJ Presence of host ICAM-1 in laboratory and clinical strains of human immunodeficiency virus type 1 increases virus infectivity and CD4(+)-T- cell depletion in human lymphoid tissue, a major site of replication in vivo. J Virol 2002, 76(3):1004-1014. 11773376
242. Fortin JF Cantin R Bergeron MG Tremblay MJ Interaction between virion-bound host intercellular adhesion molecule-1 and the high-affinity state of lymphocyte function-associated antigen-1 on target cells renders R5 and X4 isolates of human immunodeficiency virus type 1 more refractory to neutralization. Virology 2000, 268(2):493-503. 10.1006/viro.2000.0190 10704357
243. Fortin JF Cantin R Tremblay MJ T cells expressing activated LFA-1 are more susceptible to infection with human immunodeficiency virus type 1 particles bearing host-encoded ICAM-1. J Virol 1998, 72(3):2105-2112. 9499066
244. Losier M Fortin JF Cantin R Bergeron MG Tremblay MJ Virion-bound ICAM-1 and activated LFA-1: A combination of factors conferring resistance to neutralization by sera from human immunodeficiency virus type 1-infected individuals independently of the disease status and phase Clin Immunol 2003, 108(2):111-118. 10.1016/S1521-6616(03)00093-7 12921757
245. Hioe CE Chien PC Jr. Lu C Springer TA Wang XH Bandres J Tuen M LFA-1 expression on target cells promotes human immunodeficiency virus type 1 infection and transmission. J Virol 2001, 75(2);1077-1082. 10.1128/ JVI.75.2.1077-1082.2001 11134324
246. Tardif MR Tremblay MJ LFA-1 is a key determinant for preferential infection of memory CD4+ T cells by human immunodeficiency virus type 1. J Virol 2005 79 21 13714 13724 10.1128/JVI.79.21.13714-13724.2005 16227291
247. Papa A Danese S Urgesi R Grillo A Guglielmo S Roberto I Semeraro S Scaldaferri F Pola R Flex A Fedeli G Gasbarrini G Pola P Gasbarrini A Intercellular adhesion molecule 1 gene polymorphisms in inflammatory bowel disease. Eur Rev Med Pharmacol Sci 2004, 8(5):187-191. 15638228
248. Hoxie JA Fitzharris TP Youngbar PR Matthews DM Rackowski JL Radka SF Nonrandom association of cellular antigens with HTLV-III virions Hum Immunol 1987 18 1 39 52 10.1016/0198-8859(87)90111-X 3542913
249. Orentas RJ Hildreth JE Association of host cell surface adhesion receptors and other membrane proteins with HIV and SIV. AIDS Res Hum Retroviruses 1993, 9(11):1157-1165. 8312057
250. Chan WL Rodgers A Grief C Almond N Ellis S Flanagan B Silvera P Bootman J Stott J Kent K Immunization with class I human histocompatibility leukocyte antigen can protect macaques against challenge infection with SIVmac-32H. AIDS 1995, 9(3):223-228. 7755909
251. Arthur LO Bess JW Jr. Urban RG Strominger JL Morton WR Mann DL Henderson LE Benveniste RE Macaques immunized with HLA-DR are protected from challenge with simian immunodeficiency virus J Virol 1995, 69(5):3117-3124. 7707540
252. Rossio JL Bess J Jr. Henderson LE Cresswell P Arthur LO HLA class II on HIV particles is functional in superantigen presentation to human T cells: Implications for HIV pathogenesis. AIDS Res Hum Retroviruses 1995, 11(12):1433-1439. 8679286
253. Gurer C Cimarelli A Luban J Specific incorporation of heat shock protein 70 family members into primate lentiviral virions. J Virol 2002, 76(9):4666-4670. 10.1128/JVI.76.9.4666-4670.2002 11932435
254. Yung E Sorin M Pal A Craig E Morozov A Delattre O Kappes J Ott D Kalpana GV Inhibition of HIV-1 virion production by a transdominant mutant of integrase interactor 1. Nat Med 2001, 7(8):920-926. 10.1038/90959 11479624
255. Halwani R Cen S Javanbakht H Saadatmand J Kim S Shiba K Kleiman L Cellular distribution of Lysyl-tRNA synthetase and its interaction with Gag during human immunodeficiency virus type 1 assembly J Virol 2004, 78(14):7553-7564. 10.1128/JVI.78.14.7553-7564.2004 15220430
256. Javanbakht H Halwani R Cen S Saadatmand J Musier-Forsyth K Gottlinger H Kleiman L The interaction between HIV-1 Gag and human lysyl-tRNA synthetase during viral assembly J Biol Chem 2003, 278(30):27644-27651. 10.1074/jbc.M301840200 12756246
257. Kleiman L Halwani R Javanbakht H The selective packaging and annealing of primer tRNALys3 in HIV-1 Curr HIV Res 2004, 2(2):163-175. 10.2174/ 1570162043484988 15078180
258. Chertova E Bess Jr JW Jr. Crise BJ Sowder IR Schaden TM Hilburn JM Hoxie JA Benveniste RE Lifson JD Henderson LE Arthur LO Envelope glycoprotein incorporation, not shedding of surface envelope glycoprotein (gp120/SU), Is the primary determinant of SU content of purified human immunodeficiency virus type 1 and simian immunodeficiency virus. J Virol 2002, 76(11):5315-5325. 10.1128/JVI.76.11.5315-5325.2002 11991960
259. Freed EO Martin MA Virion incorporation of envelope glycoproteins with long but not short cytoplasmic tails is blocked by specific, single amino acid substitutions in the human immunodeficiency virus type 1 matrix J Virol 1995, 69:1984-1989. 7853546
260. Freed EO Martin MA Domains of the human immunodeficiency virus type 1 matrix and gp41 cytoplasmic tail required for envelope incorporation into virions J Virol 1996, 70:341-351. 8523546
261. Freed EO Orenstein JM Buckler White AJ Martin MA Single amino acid changes in the human immunodeficiency virus type 1 matrix protein block virus particle production. J Virol 1994, 68:5311-5320. 8035531
262. West JT Weldon SK Wyss S Lin X Yu Q Thali M Hunter E Mutation of the dominant endocytosis motif in human immunodeficiency virus type 1 gp41 can complement matrix mutations without increasing Env incorporation. J Virol 2002, 76(7):3338-3349. 10.1128/JVI.76.7.3338-3349.2002 11884559
263. Blot G Janvier K Le Panse S Benarous R Berlioz-Torrent C Targeting of the human immunodeficiency virus type 1 envelope to the trans-Golgi network through binding to TIP47 is required for env incorporation into virions and infectivity. J Virol 2003, 77(12):6931-6945. 10.1128/ JVI.77.12.6931-6945.2003 12768012
264. Lopez-Verges S Camus G Blot G Beauvoir R Benarous R Berlioz-Torrent C Tail-interacting protein TIP47 is a connector between Gag and Env and is required for Env incorporation into HIV-1 virions. Proc Natl Acad Sci USA 2006, 103(40):14947-14952. 10.1073/pnas.0602941103 17003132
265. Lama J The physiological relevance of CD4 receptor down-modulation during HIV infection. Curr HIV Res 2003, 1:167-184. 10.2174/ 1570162033485276 15043201
266. Cortes MJ Wong-Staal F Lama J Cell surface CD4 interferes with the infectivity of HIV-1 particles released from T cells. J Biol Chem 2002, 277(3):1770-1779. 10.1074/jbc.M109807200 11704677
267. Lama J Mangasarian A Trono D Cell-surface expression of CD4 reduces HIV-1 infectivity by blocking Env incorporation in a Nef- and Vpu-inhibitable manner. Curr Biol 1999, 9:622-631. 10.1016/ S0960-9822(99)80284-X 10375528
268. Chen BK Gandhi RT Baltimore D CD4 down-modulation during infection of human T cells with human immunodeficiency virus type 1 involves independent activities of vpu, env, and nef. J Virol 1996, 70:6044-6053. 8709227
269. Wildum S Schindler M Munch J Kirchhoff F Contribution of Vpu, Env, and Nef to CD4 down-modulation and resistance of human immunodeficiency virus type 1-infected T cells to superinfection. J Virol 2006, 80(16):8047-8059. 10.1128/JVI.00252-06 16873261
270. Glushakova S Munch J Carl S Greenough TC Sullivan JL Margolis L Kirchhoff F CD4 down-modulation by human immunodeficiency virus type 1 Nef correlates with the efficiency of viral replication and with CD4(+) T- cell depletion in human lymphoid tissue ex vivo. J Virol 2001, 75(21):10113-10117. 10.1128/JVI.75.21.10113-10117.2001 11581379
271. Lundquist CA Tobiume M Zhou J Unutmaz D Aiken C Nef-mediated downregulation of CD4 enhances human immunodeficiency virus type 1 replication in primary T lymphocytes. J Virol 2002, 76(9);4625-4633. 10.1128/JVI.76.9.4625-4633.2002 11932428
272. Stoddart CA Geleziunas R Ferrell S Linquist-Stepps V Moreno ME Bare C Xu W Yonemoto W Bresnahan PA McCune JM Greene WC Human immunodeficienty virus type 1 Nef-mediated downregulation of CD4 correlates with Nef enhancement of viral pathogenesis. J Virol 2003, 77(3):2124-2133. 10.1128/JVI.77.3.2124-2133.2003 12525647
273. Arganaraz ER Schindler M Kirchhoff F Cortes MJ Lama J Enhanced CD4 down-modulation by late-stage HIV-1 nef alleles is associated with increased Env incorporation and viral replication. J Biol Chem 2003, 36:33912-33919. 10.1074/jbc.M303679200
274. Carl S Greenough TC Krumbiegel M Greenberg M Skowronski J Sullivan JL Kirchhoff F Modulation of different human immunodeficiency virus type 1 nef functions during progression to AIDS. J Virol 2001, 75(8):3657-3665. 10.1128/JVI.75.8.3657-3665.2001 11264355
275. Brambilla A Turchetto L Gatti A Bovolenta C Veglia F Santagostino E Gringeri A Clementi M Poli G Bagnarelli P Vicenzi E Defective nef alleles in a cohort of hemophiliacs with progressing and nonprogressing HIV-1 infection. Virology 1999, 259(2):349-368. 10.1006/viro.1999.9783 10388660
276. Geffin R Wolf D Muller R Hill MD Stellwag E Freitag M Sass G Scott GB Baur AS Functional and structural defects in HIV type 1 nef genes derived from pediatric long-term survivors. AIDS Res Hum Retroviruses 2000, 16(17):1855-1868. 10.1089/08892220050195810 11118071
277. Rhodes DI Ashton L Solomon A Carr A Cooper D Kaldor J Deacon N Characterization of three nef-defective human immunodeficiency virus type 1 strains associated with long-term nonprogression. Australian Long-Term Nonprogressor Study Group. J Virol 2000, 74(22):10581-10588. 10.1128/JVI.74.22.10581-10588.2000 11044102
278. Tobiume M Takahoko M Yamada T Tatsumi M Iwamoto A Matsuda M Inefficient enhancement of viral infectivity and CD4 downregulation by human immunodeficiency virus type 1 Nef from Japanese long-term nonprogressors. J Virol 2002, 76(12):5959-5965. 10.1128/ JVI.76.12.5959-5965.2002 12021328
279. Coleman SH Day JR Guatelli J The HIV-1 Nef protein as a target for antiretroviral therapy. Emerg Ther Targets 2001, 5(1):1-22. 10.1517/ 14728222.5.1.1
280. Kedzierska K Crowe SM Cytokines and HIV-1: Interactions and clinical implications. Antivir Chem Chemother 2001, 12(3):133-150. 12959322
281. Jacques C Gosset M Berenbaum F Gabay C The role of IL-1 and IL-1Ra in joint inflammation and cartilage degradation. Vitam Horm 2006, 74:371-403. 17027524
282. Do H Vasilescu A Carpentier W Meyer L Diop G Hirtzig T Coulonges C Labib T Spadoni JL Therwath A Lathrop M Matsuda F Zagury JF Exhaustive genotyping of the interleukin-1 family genes and associations with AIDS progression in a French cohort. J Infect Dis 2006, 194(11):1492-1504. 10.1086/508545 17083033
283. Kinter A Fauci AS Interleukin-2 and human immunodeficiency virus infection: Pathogenic mechanisms and potential for immunologic enhancement. Immunol Res 1996, 15(1):1-15. 8739561
284. Shrestha S Strathdee SA Galai N Oleksyk T Fallin MD Mehta S Schaid D Vlahov D O'Brien SJ Smith MW Behavioral risk exposure and host genetics of susceptibility to HIV-1 infection. J Infect Dis 2006, 193(1):16-26. 10.1086/498532 16323127
285. Modi WS O'Brien TR Vlahov D Buchbinder S Gomperts E Phair J O'Brien SJ Winkler C Haplotype diversity in the interleukin-4 gene is not associated with HIV-1 transmission and AIDS progression. Immunogenetics 2003, 55(3):157-164. 10.1007/s00251-003-0541-5 12715242
286. Vasilescu A Heath SC Ivanova R Hendel H Do H Mazoyer A Khadivpour E Goutalier FX Khalili K Rappaport J Lathrop GM Matsuda F Zagury JF Genomic analysis of Th1-Th2 cytokine genes in an AIDS cohort: identification of IL4 and IL10 haplotypes associated with the disease progression. Genes Immun 2003, 4(6):441-449. 10.1038/sj.gene.6363983 12944981
287. Soriano A Lozano F Oliva H Garcia F Nomdedeu M De Lazzari E Rodriguez C Barrasa A Lorenzo JI Del Romero J Plana M Miro JM Gatell JM Vives J Gallart T Polymorphisms in the interleukin-4 receptor alpha chain gene influence susceptibility to HIV-1 infection and its progression to AIDS. Immunogenetics 2005, 57(9):644-654. 10.1007/s00251-005-0041-x 16189667
288. Maciaszek JW Parada NA Cruikshank WW Center DM Kornfeld H Viglianti GA IL-16 represses HIV-1 promoter activity. J Immunol 1997, 158(1):5-8. 8977168
289. Zhou P Goldstein S Devadas K Tewari D Notkins AL Human CD4+ cells transfected with IL-16 cDNA are resistant to HIV-1 infection: Inhibition of mRNA expression. Nat Med 1997, 3(6):659-664. 10.1038/nm0697-659 9176493
290. Kornfeld H Cruikshank WW Prospects for IL-16 in the treatment of AIDS. Expert Opin Biol Ther 2001, 1(3):425-432. 10.1517/14712598.1.3.425 11727516
291. Scala E D'Offizi G Rosso R Turriziani O Ferrara R Mazzone AM Antonelli G Aiuti F Paganelli R C-C chemokines, IL-16, and soluble antiviral factor activity are increased in cloned T cells from subjects with long-term nonprogressive HIV. infection J Immunol 1997, 158(9):4485-4492. 9127015
292. Amiel C Darcissac E Truong MJ Dewulf J Loyens M Mouton Y Capron A Bahr GM Interleukin-16 (IL-16) inhibits human immunodeficiency virus replication in cells from infected subjects, and serum IL-16 levels drop with disease progression. J Infect Dis 1999 179 1 83 91 10.1086/314550 9841826
293. Bader A Brockmeyer N Schnaitmann E Mertins L Otteken A Kurth R Werner A Interleukin-16 serum levels during the course of HIV-1 infection. AIDS 2001, 15(4):528-529. 10.1097/00002030-200103090-00014 11242152
294. Nakayama EE Wasi C Ajisawa A Iwamoto A Shioda T A new polymorphism in the promoter region of the human interleukin-16 (IL-16) gene. Genes Immun 2000, 1(4):293-294. 10.1038/sj.gene.6363672 11196708
295. Stylianou E Bjerkeli V Yndestad A Heggelund L Waehre T Damas JK Aukrust P Froland SS Raised serum levels of interleukin-18 is associated with disease progression and may contribute to virological treatment failure in HIV-1-infected patients. Clin Exp Immunol 2003, 132(3):462-466. 10.1046/j.1365-2249.2003.02179.x 12780693
296. Wiercinska-Drapalo A Jaroszewicz J Flisiak R Prokopowicz D Plasma interleukin-18 is associated with viral load and disease progression in HIV-1-infected patients. Microbes Infect 2004, 6(14):1273-1277. 10.1016/ j.micinf.2004.07.009 15555533
297. Torre D Pugliese A Interleukin-18: A proinflammatory cytokine in HIV-1 infection. Curr HIV Res 2006 4 4 423 430 10.2174/157016206778559993 17073617
298. Segat L Bevilacqua D Boniotto M Arraes LC de Souza PR de Lima Filho JL Crovella S IL-18 gene promoter polymorphism is involved in HIV-1 infection in a Brazilian pediatric population. Immunogenetics 2006 58 5-6 471 473 10.1007/s00251-006-0104-7 16738942
299. Song W Wilson CM Allen S Wang C Li Y Kaslow RA Tang J Interleukin 18 and human immunodeficiency virus type I infection in adolescents and adults. Clin Exp Immunol 2006, 144(1):117-124. 10.1111/j.1365-2249.2006.03050.x 16542373
300. Biron CA Role of early cytokines, including alpha and beta interferons (IFN-alpha/beta), in innate and adaptive immune responses to viral infections. Semin Immunol 1998, 10(5):383-390. 10.1006/smim.1998.0138 9799713
301. Diop G Hirtzig T Do H Coulonges C Vasilescu A Labib T Spadoni JL Therwath A Lathrop M Matsuda F Zagury JF Exhaustive genotyping of the interferon alpha receptor 1 (IFNAR1) gene and association of an IFNAR1 protein variant with AIDS progression or susceptibility to HIV-1 infection in a French AIDS cohort. Biomed Pharmacother 2006, 60(9):569-577. 10.1016/j.biopha.2006.08.002 17027223
302. Bafica A Scanga CA Schito M Chaussabel D Sher A Influence of coinfecting pathogens on HIV expression: Evidence for a role of Toll-like receptors. J Immunol 2004, 172(1):7229-7234. 15187096
303. Finberg RW Wang JP Kurt-Jones EA Toll like receptors and viruses Rev Med Virol 2007, 17(1):35-43. 10.1002/rmv.525 17146842
304. Bentwich Z Kalinkovich A Weisman Z Immune activation is a dominant factor in the pathogenesis of African AIDS. Immunol Today 1995, 16(4):187-191. 10.1016/0167-5699(95)80119-7 7734046
305. Quinn TC Piot P McCormick JB Feinsod FM Taelman H Kapita B Stevens W Fauci AS Serologic and immunologic studies in patients with AIDS in North America and Africa. The potential role of infectious agents as cofactors in human immunodeficiency virus infection. JAMA 1987, 257(19):2617-2621. 10.1001/jama.257.19.2617 3494857
306. Akira S TLR signaling. Curr Top Microbiol Immunol 2006, 311:1-16. 17048703
307. Pomerantz RJ Feinberg MB Trono D Baltimore D Lipopolysaccharide is a potent monocyte/macrophage-specific stimulator of human immunodeficiency virus type 1 expression. J Exp Med 1990, 172(1):253-261. 10.1084/ jem.172.1.253 2193097
308. Schlaepfer E Audige A Joller H Speck RF TLR7/8 triggering exerts opposing effects in acute versus latent HIV infection J Immunol 2006, 176(5);2888-2895. 16493046
309. Agrawal S Martin RR Was induction of HIV-1 through TLR9? J Immunol 2003, 171(4):1621. 12902456
310. Bafica A Scanga CA Schito ML Hieny S Sher A Cutting edge: In vivo induction of integrated HIV-1 expression by mycobacteria is critically dependent on Toll-like receptor 2 J Immunol 2003, 171(3):1123-1127. 12874196
311. Equils O Faure E Thomas L Bulut Y Trushin S Arditi M Bacterial lipopolysaccharide activates HIV long terminal repeat through Toll-like receptor 4. J Immunol 2001, 166(4):2342-2347. 11160291
312. Equils O Schito ML Karahashi H Madak Z Yarali A Michelsen KS Sher A Arditi M Toll-like receptor 2 (TLR2) and TLR9 signaling results in HIV-long terminal repeat trans-activation and HIV replication in HIV-1 transgenic mouse spleen cells: Implications of simultaneous activation of TLRs on HIV replication. J Immunol 2003, 170(10):5159-5164. 12734363
313. Sundstrom JB Little DM Villinger F Ellis JE Ansari AA Signaling through Toll-like receptors triggers HIV-1 replication in latently infected mast cells. J Immunol 2004, 172(7):4391-4401. 15034054
314. Toossi Z Virological and immunological impact of tuberculosis on human immunodeficiency virus type 1 disease J Infect Dis 2003, 1889(8):1146-1155. 10.1086/378676 14551885
315. Agrawal S Importance of nucleotide sequence and chemical modifications of antisense oligonucleotides. Biochim Biophys Acta 1999, 14899(1):53-68. 10806997
316. Lisziewicz J Sun D Weichold FF Thierry AR Lusso P Tang J Gallo RC Agrawal S Antisense oligodeoxynucleotide phosphorothioate complementary to Gag mRNA blocks replication of human immunodeficiency virus type 1 in human peripheral blood cells. Proc Natl Acad Sci USA 1994, 91(17):7942-7946. 10.1073/pnas.91.17.7942 8058738
317. Bochud PY Hersberger M Taffe P Bochud M Stein CM Rodrigues SD Calandra T Francioli P Telenti A Speck RF Aderem A Polymorphisms in Toll-like receptor 9 influence the clinical course of HIV-1 infection. AIDS 2007, 219(4):441-446. 10.1097/QAD.0b013e328012b8ac 17301562
318. Abu-Raddad LJ Patnaik P Kublin JG Dual infection with HIV and malaria fuels the spread of both diseases in sub-Saharan Africa Science 2006, 31(5805):1603-1606. 10.1126/science.1132338 17158329
319. Kublin JG Patnaik P Jere CS Miller WC Hoffman IF Chimbiya N Pendame R Taylor TE Molyneux ME Effect of Plasmodium falciparum malaria on concentration of HIV-1-RNA in the blood of adults in rural Malawi: A prospective cohort study Lancet 2005, 365(9455):233-240. 15652606
320. Patnaik P Jere CS Miller WC Hoffman IF Wirima J Pendame R Meshnick SR Taylor TE Molyneux ME Kublin JG Effects of HIV-1 serostatus, HIV-1 RNA concentration, and CD4 cell count on the incidence of malaria infection in a cohort of adults in rural Malawi J Infect Dis 2005, 192(6):984-991. 10.1086/432730 16107950
321. Gallagher M Malhotra I Mungai PL Wamachi AN Kioko JM Ouma JH Muchiri E King CL The effects of maternal helminth and malaria infections on mother-to-child HIV transmission AIDS 2005, 19(16):1849-1855. 10.1097/ 01.aids.0000189846.90946.5d 16227793
322. Kannangara S DeSimone JA Pomerantz RJ Attenuation of HIV-1 infection by other microbial agents. J Infect Dis 2005, 192(6):1003-1009. 10.1086/ 432767 16107952
323. Grivel JC Ito Y Faga G Santoro F Shaheen F Malnati MS Fitzgerald W Lusso P Margolis L Suppression of CCR5- but not CXCR4-tropic HIV-1 in lymphoid tissue by human herpesvirus 6. Nat Med 2001, 7(11):1232-1235. 10.1038/ nm1101-1232 11689888
324. Lisco A Grivel JC Biancotto A Vanpouille C Origgi F Malnati MS Schols D Lusso P Margolis LB Viral interactions in human lymphoid tissue: Human herpesvirus 7 suppresses the replication of CCR5-tropic human immunodeficiency virus type 1 via CD4 modulation. J Virol 2007, 81(2):708-717. 10.1128/JVI.01367-06 17065205
325. Wallace PK Howell AL Fanger MW Role of Fc gamma receptors in cancer and infectious disease. J Leukoc Biol 1994, 55(6):816-826. 8195706
326. Brouwer KC Lal RB Mirel LB Yang C van Eijk AM Ayisi J Otieno J Nahlen BL Steketee R Lal AA Shi YP Polymorphism of Fc receptor IIa for IgG in infants is associated with susceptibility to perinatal HIV-1 infection. AIDS 2004, 18(8):1187-1194. 10.1097/00002030-200405210-00012 15166534
327. Shi YP Nahlen BL Kariuki S Urdahl KB McElroy PD Roberts JM Lal AA Fcgamma receptor IIa (CD32) polymorphism is associated with protection of infants against high-density Plasmodium falciparum infection. VII. Asembo Bay Cohort Project J Infect Dis 2001, 1849(1):107-111. 10.1086/ 320999 11398118
328. Griffiths GM Protein sorting and secretion during CTL killing. Semin Immunol 1997, 9(2):109-115. 10.1006/smim.1997.0059 9194221
329. Migueles SA Laborico AC Shupert WL Sabbaghian MS Rabin R Hallahan CW Van Baarle D Kostense S Miedema F McLaughlin M Ehler L Metcalf J Liu S Connors M HIV-specific CD8 T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nature 2002, 3(11):1061-1068.
330. McIlroy D Meyer L Dudoit Y Samri A Delfraissy JF Autran B Debre P Theodorou I Polymorphism in the proximal promoter region of the perforin gene and its impact on the course of HIV infection. Int J Immunogenet 2006, 33(2):73-79. 10.1111/j.1744-313X.2006.00571.x 16611250